Skip to content
← All treatment topics

TREATMENT READING

Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

70 sections
  1. Follow-Up After Treatment
  2. Treatment Option Overview for Childhood Medulloblastoma
  3. Surgery
  4. Radiation therapy
  5. Chemotherapy
  6. Treatment of Childhood Medulloblastoma
  7. Treatment of younger children with medulloblastoma
  8. Surgery
  9. Adjuvant chemotherapy
  10. Desmoplastic/MBEN medulloblastoma and/or tumors with SHH signaling
  11. Nondesmoplastic, non-MBEN, and non-SHH signaling–driven medulloblastoma
  12. Treatment of children older than 3 years with average-risk medulloblastoma
  13. Surgery
  14. Adjuvant radiation therapy
  15. Adjuvant chemotherapy
  16. Treatment of children older than 3 years with high-risk medulloblastoma
  17. Surgery
  18. Adjuvant radiation therapy
  19. Adjuvant chemotherapy
  20. Treatment options under clinical evaluation for childhood medulloblastoma
  21. Treatment of Childhood Nonmedulloblastoma Embryonal Tumors
  22. Treatment of children aged 3 years and younger
  23. Treatment of children older than 3 years
  24. Surgery
  25. Adjuvant radiation therapy
  26. Adjuvant chemotherapy
  27. Treatment of Childhood Embryonal Tumors With Multilayered Rosettes or Medulloepithelioma
  28. Treatment of CNS Neuroblastoma, FOXR2-Activated
  29. Treatment Option Overview for Childhood Pineoblastoma
  30. Treatment of Childhood Pineoblastoma
  31. Treatment of children aged 3 years and younger
  32. Biopsy
  33. Adjuvant chemotherapy
  34. High-dose, marrow-ablative chemotherapy with autologous bone marrow rescue or peripheral stem cell rescue
  35. Treatment of children older than 3 years
  36. Surgery
  37. Adjuvant radiation therapy
  38. Adjuvant chemotherapy
  39. Treatment options under clinical evaluation for childhood pineoblastoma
  40. Treatment of Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors
  41. Treatment Options
  42. Surgery
  43. Radiation therapy
  44. Chemotherapy
  45. High-dose chemotherapy with stem cell rescue
  46. Molecularly targeted therapy
  47. Treatment Options Under Clinical Evaluation for Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors
  48. Certain factors affect prognosis (chance of recovery) and treatment options.
  49. Medulloblastoma, other CNS embryonal tumors, and pineoblastoma in children are treated based on the tumor type and the child's age.
  50. Treatment of medulloblastoma in children older than 3 years also depends on whether the tumor is average risk or high risk.
  51. Average risk
  52. High risk
  53. The results of the tests and procedures done to diagnose medulloblastoma, other CNS embryonal tumors, and pineoblastoma in children are used to plan cancer treatment.
  54. Sometimes childhood medulloblastoma and other central nervous system embryonal tumors come back after treatment.
  55. Treatment Option Overview
  56. Key Points
  57. There are different types of treatment for children who have medulloblastoma and other central nervous system (CNS) embryonal tumors.
  58. Children who have medulloblastoma, other CNS embryonal tumors, and pineoblastoma should have their treatment planned by a team of health care providers who are experts in treating brain tumors in children.
  59. The following types of treatment may be used:
  60. Surgery
  61. Radiation therapy
  62. Chemotherapy
  63. High-dose chemotherapy with autologous stem cell rescue
  64. Targeted therapy
  65. New types of treatment are being tested in clinical trials.
  66. Treatment of Childhood Medulloblastoma
  67. Treatment of Other CNS Embryonal (nonmedulloblastoma) Tumors in Children
  68. Treatment of Childhood Pineoblastoma
  69. Treatment of Recurrent Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors
  70. The tumor and the treatment may cause symptoms that continue after treatment ends.

Health professional · General Information About Medulloblastoma and Other Central Nervous System (CNS) Embryonal Tumors

Follow-Up After Treatment

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Relapse in children with embryonal tumors is most likely to occur within the first 18 months of diagnosis.[43,64] Surveillance imaging of the brain and spine is usually undertaken at routine intervals during and after treatment (see Table 2). The frequency of such imaging, designed to detect recurrent disease at an early, asymptomatic state, has been arbitrarily determined and has not been shown to clearly influence survival.[65-68] Growth hormone replacement therapy has not been shown to increase the likelihood of disease relapse and should not impact the frequency of surveillance testing.[37]

Sources: 43 · 64 · Table 2 · 65 · 68 · 37

Table 2. Surveillance Testing During and After Treatment for Medulloblastoma and Other Central Nervous System Embryonal Tumors
Surveillance PeriodFrequency of Visits During Surveillance PeriodTesting
MRI = magnetic resonance imaging.
aFor pineoblastoma, continue spinal evaluations every 6 months until 5 years from diagnosis. Although these suggestions are based on a small sample size, there is evidence for continuing surveillance testing of the spine until 5 years after diagnosis.[69]
First 3 years after diagnosisEvery 3 monthsPhysical examination
Imaging of the brain every 3 months for the first 3 years, then every 6 months for the ensuing 2 years, and then as per preference of the treating physician or per protocol; MRI of the spine every 3 months for the first 2 years, then every 6 months for 1 year, and then as per preference of the treating physician or per protocola
Endocrinology evaluation once a year
Neuropsychological testing every 1–2 years
3–5 years after diagnosisEvery 6 monthsPhysical examination
Imaging of the brain and spine once a year
Endocrinology evaluation once a year
Neuropsychological testing every 1–2 years
More than 5 years after diagnosisOnce a yearPhysical examination
Imaging of the brain once a year
Endocrinology evaluation once a year
Neuropsychological testing every 1–2 years (optional)

Sources: 69

The development of surveillance strategies other than imaging for patients with medulloblastoma is the subject of ongoing research. In one study of 134 children with newly diagnosed medulloblastoma, copy number variants were detected at baseline in 123 patients (92%) by primary tumor testing and in 65 patients (49%) by CSF testing. Copy number variants were detected more frequently in the CSF of patients with disseminated disease and in those with subsequent progression. Prospective studies will be necessary to evaluate the potential for CSF copy number analysis to become a component of surveillance testing, as a measure of medulloblastoma minimal residual disease and early relapse.[51]

Sources: 51

Childhood and adolescent cancer survivors require close monitoring because cancer therapy side effects may persist or develop months or years after treatment. For specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.

Sources: Late Effects of Treatment for Childhood Cancer

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Childhood Medulloblastoma

Treatment Option Overview for Childhood Medulloblastoma

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Table 3 describes the standard treatment options for newly diagnosed and recurrent childhood medulloblastoma.

Sources: Table 3

Table 3. Standard Treatment Options for Childhood Medulloblastoma
Treatment GroupStandard Treatment Options
Newly diagnosed childhood medulloblastomaYounger children with medulloblastomaSurgery
Adjuvant chemotherapy
Children older than 3 years with average-risk medulloblastomaSurgery
Adjuvant radiation therapy
Adjuvant chemotherapy
Children older than 3 years with high-risk medulloblastomaSurgery
Adjuvant radiation therapy
Adjuvant chemotherapy
Recurrent childhood medulloblastomaThere are no standard treatment options. For more information, see the Treatment of Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors section.

Sources: Surgery · Adjuvant chemotherapy · Surgery · Adjuvant radiation therapy · Adjuvant chemotherapy · Surgery · Adjuvant radiation therapy · Adjuvant chemotherapy · Treatment of Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors

Health professional · Childhood Medulloblastoma / Treatment Option Overview for Childhood Medulloblastoma

Surgery

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Surgery is considered a standard part of treatment for histological confirmation of tumor type and as a means to improve outcome. Total or near-total resections are considered optimal if they can be performed safely.[84,85]

Sources: 84 · 85

Postoperatively, children may have significant neurological deficits caused by preoperative tumor-related brain injury, hydrocephalus, or surgery-related brain injury.[86][Level of evidence C1] A significant number of patients with medulloblastoma develop cerebellar mutism syndrome (also known as posterior fossa syndrome). Symptoms of cerebellar mutism syndrome, which usually appear within 1 or 2 days after surgery, include the following:

Sources: 86 · Level of evidence C1

Loss of speech.

Suprabulbar palsies.

Ataxia.

Hypotonia.

Emotional lability.

The etiology of cerebellar mutism syndrome remains unclear, although cerebellar vermian damage and/or disruption of cerebellar-cortical tracts has been postulated as the possible cause of the mutism.[87,88]; [89][Level of evidence C1] In two Children’s Cancer Group studies that evaluated children with both average-risk and high-risk medulloblastoma, the syndrome was identified in nearly 25% of patients.[88-90]; [91][Level of evidence C1] A retrospective analysis of 370 patients with medulloblastoma identified younger age, larger tumor size, and midline tumor location as risk factors for developing mutism. This finding is consistent with previous observations. Investigators also observed a correlation between medulloblastoma subtype and risk of mutism. Mutism was more common in patients with group 3 and group 4 medulloblastomas (30%–35% of patients) and less frequent in children with SHH-activated tumors (7% of patients).[92] A prospective study that included longitudinal neurological examination of 178 patients with medulloblastoma identified similar risk factors for mutism (higher risk with younger age; lower risk with SHH subtype), most likely because SHH-activated tumors tend to be located in the hemispheres and not in the midline. The study also reported a higher risk of developing mutism in patients who undergo tumor resections at low-volume surgery centers.[93] Approximately 50% of patients with this syndrome manifest long-term, permanent neurological and neurocognitive sequelae.[89,91]

Sources: 87 · 88 · 89 · Level of evidence C1 · 88 · 90 · 91 · Level of evidence C1 · 92 · 93 · 89 · 91

Health professional · Childhood Medulloblastoma / Treatment Option Overview for Childhood Medulloblastoma

Radiation therapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Radiation therapy to the primary tumor site is usually in the range of 54 Gy to 55.8 Gy.[94] In most instances, this therapy is given with a margin of 1 cm to 2 cm around the primary tumor site, preferably by conformal techniques.[94] Reducing boost volumes for the whole posterior fossa and to the tumor bed plus margins did not compromise outcomes in average-risk patients in the Children's Oncology Group (COG) ACNS0331 (NCT00085735) study.[59][Level of evidence A1] For all medulloblastomas in children older than 3 or 4 years at diagnosis, craniospinal radiation therapy is given at doses ranging between 23.4 Gy and 36 Gy, depending on risk factors such as extent of disease at diagnosis. A prospective phase II toxicity study of proton radiation therapy [95] and a retrospective efficacy report of protons versus photons for medulloblastoma [96] demonstrated equivalent outcomes for PFS, overall survival (OS), patterns of relapse, and delayed toxic effects. A retrospective study of 84 children who received either proton (n = 38) or photon (n = 46) radiation therapy demonstrated similar rates of grade 3 and grade 4 ototoxicity despite low mean cochlear doses in children who received proton radiation therapy, suggesting that other factors (e.g. cisplatin, initial tumor location in relationship to the vestibulocochlear nerve [eighth cranial nerve]) contribute to ototoxicity.[97] The comparative outcomes of these treatment technologies are under investigation.

Sources: 94 · 94 · ACNS0331 (NCT00085735) · 59 · Level of evidence A1 · 95 · 96 · 97

Chemotherapy is usually administered during and after radiation therapy.

For children younger than 3 years, efforts are made to omit or delay radiation therapy, given the profound impact of radiation at this age. Children of all ages are susceptible to the adverse effects of radiation on brain development. Debilitating effects on neurocognitive development, growth, and endocrine function have been frequently observed, especially in younger children.[98-102]

Sources: 98 · 102

Health professional · Childhood Medulloblastoma / Treatment Option Overview for Childhood Medulloblastoma

Chemotherapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Chemotherapy, usually given during and after radiation therapy, is a standard component of treatment for older children with medulloblastoma and other embryonal tumors. Chemotherapy can be used to delay and sometimes obviate the need for radiation therapy in 20% to 40% of children younger than 3 to 4 years with nondisseminated medulloblastoma.[103,104]; [102][Level of evidence C1]

Sources: 103 · 104 · 102 · Level of evidence C1

Health professional · Childhood Medulloblastoma

Treatment of Childhood Medulloblastoma

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Health professional · Childhood Medulloblastoma / Treatment of Childhood Medulloblastoma

Treatment of younger children with medulloblastoma

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

The 5-year event-free survival (EFS) rates for young children with medulloblastoma, arbitrarily described in the past as aged 3 years and younger at diagnosis, have ranged between 30% and 70%. There is no consensus as to what age constitutes a younger population of children with medulloblastoma who are best treated with immediate postsurgery chemotherapy and delayed or no radiation therapy. Most studies agree that in patients aged 3 years and younger, initial chemotherapy should be strongly considered. In patients between the ages of 3 and 4 years, and possibly as old as age 5 years, some investigators have recommended that radiation therapy be delayed or omitted entirely. Such decisions are based on multiple factors, including histological subtype, molecular subtype, extent of disease at diagnosis, preexisting neurological and neurodevelopmental status, and family preferences. Most long-term survivors who have been successfully treated with chemotherapy alone have had nondisseminated completely resected tumors.[81,103,105]; [106][Level of evidence B4] Several studies that have used chemotherapy alone for younger patients have observed that the finding of desmoplasia (seen in patients with desmoplastic medulloblastoma or MBEN) and/or molecular evidence of SHH signaling suggests a significantly better prognosis than the finding of classic or large cell/anaplastic medulloblastoma.[7,27,66-68]; [82][Level of evidence B4]

Sources: 81 · 103 · 105 · 106 · Level of evidence B4 · 7 · 27 · 66 · 68 · 82 · Level of evidence B4

The treatment of younger children with newly diagnosed medulloblastoma continues to evolve. Results have been variable, and comparison across studies has been difficult because of differences in the drug regimens used and the utilization of craniospinal and local boost radiation therapy at the end of chemotherapy or when children reached age 3 years in some studies.

Standard treatment options for younger children with newly diagnosed medulloblastoma include the following:

Surgery.

Sources: Surgery

Adjuvant chemotherapy.

Sources: Adjuvant chemotherapy

Health professional · Childhood Medulloblastoma / Treatment of Childhood Medulloblastoma / Treatment of younger children with medulloblastoma

Surgery

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

If feasible, complete surgical resection of the tumor is the optimal treatment. Surgical resectability is associated with histology, as patients with desmoplastic/nodular medulloblastoma or MBEN have a higher rate of complete resection than patients with classic medulloblastoma.[67,68]

Sources: 67 · 68

Health professional · Childhood Medulloblastoma / Treatment of Childhood Medulloblastoma / Treatment of younger children with medulloblastoma

Adjuvant chemotherapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Therapies for younger children with medulloblastoma have included the use of multiagent chemotherapeutic approaches, including drugs such as cyclophosphamide, etoposide, cisplatin, and vincristine, with or without concomitant high-dose intravenous and/or intraventricular methotrexate.[68,81,103,105,107,108]; [109,110][Level of evidence B4] The efficacy of chemotherapy has varied, depending on the histology and/or molecular subtype of the tumor.

Sources: 68 · 81 · 103 · 105 · 107 · 108 · 109 · 110 · Level of evidence B4

Health professional · Childhood Medulloblastoma / Treatment of Childhood Medulloblastoma / Treatment of younger children with medulloblastoma / Adjuvant chemotherapy

Desmoplastic/MBEN medulloblastoma and/or tumors with SHH signaling

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

A series of studies have demonstrated that intensive chemotherapy, including either high-dose systemic and intraventricular methotrexate or high-dose chemotherapy supported by stem cell rescue, without radiation therapy, is an effective treatment for most infants and very young children with medulloblastoma.

Evidence (chemotherapy):

In the German Hirntumor (HIT) 2000 multicenter trial, a multiagent chemotherapy regimen that included high-dose intravenous and intraventricular methotrexate was used. This drug regimen did not include high-dose chemotherapy supported by bone marrow or peripheral stem cell rescue.[81]

Sources: 81

In the German Hirntumor (HIT) 2000 multicenter trial, a multiagent chemotherapy regimen that included high-dose intravenous and intraventricular methotrexate was used. This drug regimen did not include high-dose chemotherapy supported by bone marrow or peripheral stem cell rescue.[81]

Nineteen patients with desmoplastic medulloblastoma or MBEN had a 5-year EFS rate of 90% (±7%) and an OS rate of 100% (±0%).

All patients were treated with postoperative chemotherapy alone, and no radiation was given before progression.

An expanded cohort of the German HIT 2000 trial included an additional 23 children with nodular desmoplasia or MBEN who were treated with the same regimen. The following results were reported:[111]

Sources: 111

An expanded cohort of the German HIT 2000 trial included an additional 23 children with nodular desmoplasia or MBEN who were treated with the same regimen. The following results were reported:[111]

Combined results confirmed the excellent survival, with a 5-year EFS rate of greater than 90%.

In this expanded cohort, molecular characterization was performed and a subset of tumors with SHH signaling were identified. These patients with tumors demonstrating SHH signaling had a similar excellent prognosis.

Further characterization of the SHH signaling molecular subtype by chromosomal aberrations did not identify any differences in EFS or OS.

Other studies have suggested that further subdivision by chromosomal aberrations in young children with SHH-driven medulloblastoma was predictive of outcome.

A COG clinical trial (CCG-9921) also had a favorable outcome for children with desmoplastic medulloblastoma (including MBEN). In this study, patients with desmoplastic tumors did not receive radiation therapy before progression.[103]

Sources: 103

A COG clinical trial (CCG-9921) also had a favorable outcome for children with desmoplastic medulloblastoma (including MBEN). In this study, patients with desmoplastic tumors did not receive radiation therapy before progression.[103]

Patients in the desmoplastic group achieved an EFS rate of 77% (±9%) and an OS rate of 85% (±8%), compared with an EFS rate of 17% (±5%) and an OS rate of 29% (±6%) for patients in the nondesmoplastic group (P < .0001 for both EFS and OS comparisons).

The COG-ACNS1221 (NCT02017964) study tested systemic chemotherapy that was identical to the chemotherapy used in the German HIT 2000 trial, except for the omission of intraventricular methotrexate.[28]

Sources: COG-ACNS1221 (NCT02017964) · 28

The COG-ACNS1221 (NCT02017964) study tested systemic chemotherapy that was identical to the chemotherapy used in the German HIT 2000 trial, except for the omission of intraventricular methotrexate.[28]

The study was closed early because of a higher-than-expected rate of relapse, with a 2-year PFS rate of 52% in the 25 patients who were studied.

Another treatment option for children younger than 3 years at diagnosis is high-dose chemotherapy. Results of trials using higher-dose, marrow-ablative chemotherapeutic regimens supported by stem cell rescue have also demonstrated that a subgroup of patients with medulloblastoma who are younger than 3 years and, in some studies, younger than 5 years at the time of diagnosis can be successfully treated with chemotherapy alone.[104,106,112][Level of evidence B4]; [113]

Sources: 104 · 106 · 112 · Level of evidence B4 · 113

Another treatment option for children younger than 3 years at diagnosis is high-dose chemotherapy. Results of trials using higher-dose, marrow-ablative chemotherapeutic regimens supported by stem cell rescue have also demonstrated that a subgroup of patients with medulloblastoma who are younger than 3 years and, in some studies, younger than 5 years at the time of diagnosis can be successfully treated with chemotherapy alone.[104,106,112][Level of evidence B4]; [113]

The best survival rates using this higher-dose chemotherapy approach have been seen in patients with desmoplastic medulloblastoma and MBEN.[113]

Sources: 113

Another treatment option for children younger than 3 years at diagnosis is high-dose chemotherapy. Results of trials using higher-dose, marrow-ablative chemotherapeutic regimens supported by stem cell rescue have also demonstrated that a subgroup of patients with medulloblastoma who are younger than 3 years and, in some studies, younger than 5 years at the time of diagnosis can be successfully treated with chemotherapy alone.[104,106,112][Level of evidence B4]; [113] › The best survival rates using this higher-dose chemotherapy approach have been seen in patients with desmoplastic medulloblastoma and MBEN.[113]

After treatment with chemotherapy without concomitant radiation therapy, patients with nondisseminated disease have achieved survival rates of nearly 90%, and patients with disseminated disease have achieved survival rates of 80%.

One study reported the outcomes of infants and young children with relapsed medulloblastoma who were initially treated without craniospinal irradiation (CSI).[114]

Sources: 114

One study reported the outcomes of infants and young children with relapsed medulloblastoma who were initially treated without craniospinal irradiation (CSI).[114]

A substantial portion of these children were treated with CSI-based regimens and their disease was successfully salvaged.

The 3-year postrelapse survival rate was 52.4% for patients treated with curative intent.

The report found that older age at diagnosis, local relapse, and the SHH infant medulloblastoma subtype were associated with better postrelapse survival.

The addition of chemotherapy to CSI did not improve outcomes.

Health professional · Childhood Medulloblastoma / Treatment of Childhood Medulloblastoma / Treatment of younger children with medulloblastoma / Adjuvant chemotherapy

Nondesmoplastic, non-MBEN, and non-SHH signaling–driven medulloblastoma

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Compared with children with desmoplastic medulloblastoma or MBEN treated with current intensive chemotherapy regimens, children with other histological and/or molecular subtypes fare less well. One study suggested that patients with molecularly identified group 4 tumors did well with chemotherapy alone.[111]

Sources: 111

Evidence (chemotherapy):

In children with nondesmoplastic, non-MBEN, and/or non-SHH–signaling tumors, the EFS rates are less than 40% despite the use of intensive chemotherapy supplemented with methotrexate (intravenous and intraventricular) or the use of high-dose chemotherapy regimens supported with stem cell rescue.[68,103,111,113,115]

Sources: 68 · 103 · 111 · 113 · 115

In children with nondesmoplastic, non-MBEN, and/or non-SHH–signaling tumors, the EFS rates are less than 40% despite the use of intensive chemotherapy supplemented with methotrexate (intravenous and intraventricular) or the use of high-dose chemotherapy regimens supported with stem cell rescue.[68,103,111,113,115]

Outcome is particularly poor when these patients have disseminated disease.

In some studies, radiation therapy to the primary tumor site and/or craniospinal axis has been added after chemotherapy, which makes the assessment of the efficacy of chemotherapy more difficult.[111,113,115]

Sources: 111 · 113 · 115

There is no consensus on how much radiation therapy (dose and extent) should be given and at what age radiation therapy should be instituted in young patients with localized or disseminated disease.

In the expanded HIT 2000 study, the addition of focal radiation therapy to the primary tumor site in patients with localized disease after chemotherapy did not improve EFS or OS.[111]

Sources: 111

In the St. Jude Children's Research Hospital (SJCRH) SJYC07 (NCT00602667) study, focal radiation therapy also did not improve EFS in infants with medulloblastoma denoted as intermediate risk (5-year EFS rate, 25% ± 12%).[65]

Sources: SJYC07 (NCT00602667) · 65

The COG P9934 (NCT00006461) study, which also employed focal radiation therapy, had a similar EFS (4-year EFS rate, 23% ± 12%) for patients with nondesmoplastic medulloblastoma.[116]

Sources: P9934 (NCT00006461) · 116

In the SJCRH SJYC07 study, 29 of the 54 infants with medulloblastoma whose disease progressed received CSI (median dose, 36 Gy). Of the 29 patients, 18 (62%) survived, compared with 6 of 25 patients (24%) who did not receive CSI.[65]

Sources: 65

Health professional · Childhood Medulloblastoma / Treatment of Childhood Medulloblastoma

Treatment of children older than 3 years with average-risk medulloblastoma

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Standard treatment options for children older than 3 years with newly diagnosed average-risk medulloblastoma include the following:

Surgery.

Sources: Surgery

Adjuvant radiation therapy.

Sources: Adjuvant radiation therapy

Adjuvant chemotherapy.

Sources: Adjuvant chemotherapy

Health professional · Childhood Medulloblastoma / Treatment of Childhood Medulloblastoma / Treatment of children older than 3 years with average-risk medulloblastoma

Surgery

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

If feasible, total or near-total removal of the tumor is considered optimal.[84]

Sources: 84

Health professional · Childhood Medulloblastoma / Treatment of Childhood Medulloblastoma / Treatment of children older than 3 years with average-risk medulloblastoma

Adjuvant radiation therapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Radiation therapy is usually initiated after surgery with or without concurrent chemotherapy.[117-119] The best survival results for children with medulloblastoma have been obtained when radiation therapy is initiated within 4 to 6 weeks postsurgery.[118-120]; [94,121][Level of evidence A1] A pilot study in children with WNT-activated medulloblastoma attempted to omit craniospinal radiation therapy (and treat patients with postsurgical chemotherapy alone). The study was aborted after the first two patients had early tumor recurrences.[122]

Sources: 117 · 119 · 118 · 120 · 94 · 121 · Level of evidence A1 · 122

The radiation dose for patients with average-risk medulloblastoma is 54 Gy to the posterior fossa or local tumor bed and 23.4 Gy to the entire neuraxis (i.e., the whole brain and spine), termed CSI.[117-119,123]

Sources: 117 · 119 · 123

Evidence (adjuvant radiation therapy):

With radiation therapy alone, using a craniospinal radiation dose of 35 Gy with a boost to the posterior fossa of 55 Gy, 5-year EFS rates range between 50% and 65% in patients with nondisseminated disease.[80,118]

Sources: 80 · 118

The minimal dose of craniospinal radiation needed for disease control is unknown. Attempts to lower the dose of craniospinal radiation therapy to 23.4 Gy without chemotherapy have resulted in an increased incidence of isolated leptomeningeal relapse.[123] One series attempted to treat children with WNT-activated tumors using focal radiation therapy alone, without CSI. The study showed an unacceptable incidence of neuroaxial failure with the omission of up-front CSI.[124]Lower doses and boost volume of craniospinal radiation were evaluated in a COG study (NCT00085735). Children aged 3 to 7 years were randomly assigned to receive a craniospinal radiation dose of either 18 Gy or 23.4 Gy, as well as whole posterior fossa versus limited target volume boost to the tumor bed.[59][Level of evidence A1]Analysis according to molecular subgroups demonstrated that children with group 4 medulloblastoma who received 18 Gy of craniospinal radiation therapy had poorer EFS than those who received 23.4 Gy. This was not demonstrated in the other molecular subgroups, although the study was not sized for molecular subgroup analysis.[59] Craniospinal radiation dose reduction to 18 Gy is currently being investigated in WNT medulloblastoma patients (NCT02724579), the molecular subgroup with the best prognosis.

Sources: 123 · 124 · NCT00085735 · 59 · Level of evidence A1 · 59 · NCT02724579

The minimal dose of craniospinal radiation needed for disease control is unknown. Attempts to lower the dose of craniospinal radiation therapy to 23.4 Gy without chemotherapy have resulted in an increased incidence of isolated leptomeningeal relapse.[123] One series attempted to treat children with WNT-activated tumors using focal radiation therapy alone, without CSI. The study showed an unacceptable incidence of neuroaxial failure with the omission of up-front CSI.[124]Lower doses and boost volume of craniospinal radiation were evaluated in a COG study (NCT00085735). Children aged 3 to 7 years were randomly assigned to receive a craniospinal radiation dose of either 18 Gy or 23.4 Gy, as well as whole posterior fossa versus limited target volume boost to the tumor bed.[59][Level of evidence A1]Analysis according to molecular subgroups demonstrated that children with group 4 medulloblastoma who received 18 Gy of craniospinal radiation therapy had poorer EFS than those who received 23.4 Gy. This was not demonstrated in the other molecular subgroups, although the study was not sized for molecular subgroup analysis.[59] Craniospinal radiation dose reduction to 18 Gy is currently being investigated in WNT medulloblastoma patients (NCT02724579), the molecular subgroup with the best prognosis.

Results revealed that 18 Gy of CSI was inferior to 23.4 Gy of CSI (5-year EFS rate of 82.6% ± 4.2% and OS rate of 85.8% for patients who received 23.4 Gy vs. EFS rate of 71.9% ± 4.9% and OS rate of 77.9% ± 4.9% for patients who received 18 Gy).

The 5-year EFS rate was 82.5% for patients who received radiation therapy targeting the tumor bed, compared with 80.5% for patients who received posterior fossa radiation therapy. Therefore, radiation therapy targeting the tumor bed was not inferior to posterior fossa radiation therapy (hazard ratio, 0.97; 94% upper confidence interval, 1.32).

The SIOP-PNET-4 (NCT01351870) study compared daily radiation therapy (1.8 Gy fractions with 23.4 Gy to the neuraxis and a 30 Gy boost to the posterior fossa) with twice-per-day radiation (1 Gy fractions with 36 Gy and a 24-Gy boost to the posterior fossa).[125]

Sources: SIOP-PNET-4 (NCT01351870) · 125

The SIOP-PNET-4 (NCT01351870) study compared daily radiation therapy (1.8 Gy fractions with 23.4 Gy to the neuraxis and a 30 Gy boost to the posterior fossa) with twice-per-day radiation (1 Gy fractions with 36 Gy and a 24-Gy boost to the posterior fossa).[125]

With a median follow-up of 7.8 years, the 10-year OS was not significantly different between the two radiation groups.

Long-term side effects were not reported in this study.

If chemotherapy is added after radiation therapy, 23.4 Gy of craniospinal radiation therapy has been shown to be an effective dose.[94,125-127] Lower doses are being evaluated.

Sources: 94 · 125 · 127

Although the standard boost in medulloblastoma is to the entire posterior fossa, failure data patterns reveal that radiation therapy to the tumor bed instead of the entire posterior fossa is equally effective and may be associated with reduced toxicity.[128,129]; [59][Level of evidence A1]

Sources: 128 · 129 · 59 · Level of evidence A1

Health professional · Childhood Medulloblastoma / Treatment of Childhood Medulloblastoma / Treatment of children older than 3 years with average-risk medulloblastoma

Adjuvant chemotherapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Chemotherapy is now a standard component of the treatment of children with average-risk medulloblastoma.

Evidence (adjuvant chemotherapy):

Prospective randomized trials and single-arm trials suggest that adjuvant chemotherapy given during and after radiation therapy improves OS for children with average-risk medulloblastoma.[91,117-121]

Sources: 91 · 117 · 121

Prospective randomized trials and single-arm trials suggest that adjuvant chemotherapy given during and after radiation therapy improves OS for children with average-risk medulloblastoma.[91,117-121]

Radiation therapy and chemotherapy given during and after surgery has demonstrated 5-year EFS rates of 70% to 85%.[117-119]; [130][Level of evidence B4]

Sources: 117 · 119 · 130 · Level of evidence B4

A lower radiation dose of 23.4 Gy to the neuraxis when coupled with chemotherapy has been shown to result in disease control in up to 85% of patients and may decrease the severity of long-term neurocognitive sequelae.[94,126,127,131]

Sources: 94 · 126 · 127 · 131

A variety of chemotherapeutic regimens have been successfully used, including the combination of cisplatin, lomustine, and vincristine or the combination of cisplatin, cyclophosphamide, and vincristine.[117,118,131,132] In addition, postradiation high-dose cyclophosphamide supported by peripheral stem cell rescue, but with reduced cumulative doses of vincristine and cisplatin, has resulted in similar survival rates.[58]

Sources: 117 · 118 · 131 · 132 · 58

A variety of chemotherapeutic regimens have been successfully used, including the combination of cisplatin, lomustine, and vincristine or the combination of cisplatin, cyclophosphamide, and vincristine.[117,118,131,132] In addition, postradiation high-dose cyclophosphamide supported by peripheral stem cell rescue, but with reduced cumulative doses of vincristine and cisplatin, has resulted in similar survival rates.[58]

These therapies have increased 5-year and 10-year EFS and OS rates and have likely decreased the incidence of late relapse.

However, long-term survivors treated with multimodality therapy are at a high risk of late effects such as hearing loss, cardiac complications, and secondary neoplasms.[133]

Sources: 133

Although medulloblastoma is often sensitive to chemotherapy, preradiation chemotherapy has not been shown to improve survival in patients with average-risk medulloblastoma, compared with radiation therapy and subsequent chemotherapy. In some prospective studies, preradiation chemotherapy has been related to a poorer rate of survival.[118-121]

Sources: 118 · 121

Health professional · Childhood Medulloblastoma / Treatment of Childhood Medulloblastoma

Treatment of children older than 3 years with high-risk medulloblastoma

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Standard treatment options for children older than 3 years who are newly diagnosed with medulloblastoma and have metastatic disease or have had a subtotal resection include the following:

Surgery.

Sources: Surgery

Adjuvant radiation therapy.

Sources: Adjuvant radiation therapy

Adjuvant chemotherapy.

Sources: Adjuvant chemotherapy

In high-risk patients, numerous studies have demonstrated that multimodality therapy improves the duration of disease control and overall disease-free survival.[58,134] Studies show that 50% to 70% of patients with high-risk disease, including those with metastatic disease, will experience long-term disease control.[58,117,134-138]; [139,140][Level of evidence A1]; [141][Level of evidence B4] A completed COG study demonstrated that children with group 3 MYC-amplified tumors who were randomly assigned to receive carboplatin during radiation therapy had improved 5-year EFS and OS rates, compared with those who did not receive carboplatin concurrently with radiation therapy.[135] The optimal treatment for children with SHH-activated, TP53-altered medulloblastoma has not been determined, as less than 30% of patients are expected to survive 5 years from diagnosis after treatment with current therapy.[14]

Sources: 58 · 134 · 58 · 117 · 134 · 138 · 139 · 140 · Level of evidence A1 · 141 · Level of evidence B4 · 135 · 14

Health professional · Childhood Medulloblastoma / Treatment of Childhood Medulloblastoma / Treatment of children older than 3 years with high-risk medulloblastoma

Surgery

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Treatment of high-risk patients is the same as for average-risk patients. An attempt at gross-total resection is considered optimal, if feasible.[80,84]

Sources: 80 · 84

Health professional · Childhood Medulloblastoma / Treatment of Childhood Medulloblastoma / Treatment of children older than 3 years with high-risk medulloblastoma

Adjuvant radiation therapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

In contrast to standard-risk treatment, the craniospinal radiation dose is generally 36 Gy.

Health professional · Childhood Medulloblastoma / Treatment of Childhood Medulloblastoma / Treatment of children older than 3 years with high-risk medulloblastoma

Adjuvant chemotherapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Evidence (adjuvant chemotherapy):

The drugs that are useful in children with average-risk disease are the same drugs that have been used extensively in children with high-risk disease, including cisplatin, lomustine, cyclophosphamide, etoposide, and vincristine.[139]

Sources: 139

The drugs that are useful in children with average-risk disease are the same drugs that have been used extensively in children with high-risk disease, including cisplatin, lomustine, cyclophosphamide, etoposide, and vincristine.[139]

These therapies have increased 5-year and 10-year EFS and OS rates and have likely decreased the incidence of late relapse.

However, long-term survivors treated with multimodality therapy are at a high risk of late effects such as hearing loss, cardiac complications, and secondary neoplasms.[133]

Sources: 133

Postradiation high-dose nonmyeloablative chemotherapy supported by peripheral stem cell rescue, but with reduced cumulative doses of vincristine and cisplatin, has also been used and has resulted in 5-year PFS rates of approximately 60%.[58]

Sources: 58

The COG ACNS0332 (NCT00392327) study randomly assigned patients to receive daily carboplatin compared with weekly vincristine during radiation therapy (36 Gy craniospinal plus a posterior fossa boost) followed by six cycles of adjuvant treatment with cisplatin, cyclophosphamide, and vincristine.[135]

Sources: ACNS0332 (NCT00392327) · 135

The COG ACNS0332 (NCT00392327) study randomly assigned patients to receive daily carboplatin compared with weekly vincristine during radiation therapy (36 Gy craniospinal plus a posterior fossa boost) followed by six cycles of adjuvant treatment with cisplatin, cyclophosphamide, and vincristine.[135]

Of the 261 evaluable patients, the 5-year EFS rate was 62.9%, and the OS rate was 73.4%.

For the entire cohort, there was no difference in EFS rate between patients who were treated with carboplatin (66.4%) and patients who were not treated with carboplatin (59.2%).

In a subset analysis based on molecular subgrouping, patients with group 3 medulloblastoma appeared to benefit from the use of daily carboplatin during radiation therapy, with a 5-year EFS rate of 73.2% for patients who received carboplatin, compared with 53.7% for those who did not.

A second randomization testing the utility of isotretinoin maintenance therapy was closed at the time of a planned interim analysis for futility.

In a trial of 51 patients with newly diagnosed high-risk disease, patients were treated with postoperative induction chemotherapy (etoposide and carboplatin), followed by two high-dose thiotepa courses with peripheral stem cell rescue and risk-adapted craniospinal radiation therapy.[136]

Sources: 136

In a trial of 51 patients with newly diagnosed high-risk disease, patients were treated with postoperative induction chemotherapy (etoposide and carboplatin), followed by two high-dose thiotepa courses with peripheral stem cell rescue and risk-adapted craniospinal radiation therapy.[136]

The 5-year PFS and OS rates were 76%.

Health professional · Childhood Medulloblastoma / Treatment of Childhood Medulloblastoma

Treatment options under clinical evaluation for childhood medulloblastoma

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Early-phase therapeutic trials may be available for selected patients. These trials may be available via the COG, the Pediatric Brain Tumor Consortium, or other entities. Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: COG · Pediatric Brain Tumor Consortium · NCI website · ClinicalTrials.gov website

Health professional · Childhood Nonmedulloblastoma Embryonal Tumors

Treatment of Childhood Nonmedulloblastoma Embryonal Tumors

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

For more information about the treatment of CNS AT/RTs, see Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment.

Sources: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment

For more information about the treatment of medulloepithelioma, see the Treatment of Childhood Embryonal Tumors With Multilayered Rosettes or Medulloepithelioma section.

Sources: Treatment of Childhood Embryonal Tumors With Multilayered Rosettes or Medulloepithelioma

Health professional · Childhood Nonmedulloblastoma Embryonal Tumors / Treatment of Childhood Nonmedulloblastoma Embryonal Tumors

Treatment of children aged 3 years and younger

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

The optimal treatment of childhood nonmedulloblastoma embryonal tumors remains unclear and under study. Retrospective studies of fairly large numbers of patients have suggested management approaches for the more common subgroups, including AT/RTs, ETMRs, and FOXR2-activated tumors. For more information about the treatment of AT/RTs, see Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment.

Sources: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment

Standard treatment options for children aged 3 years and younger with newly diagnosed nonmedulloblastoma embryonal tumors, excluding AT/RTs, ETMRs, and FOXR2-activated tumors, include the following:

Surgery.

Adjuvant chemotherapy.

Treatment of children aged 3 years and younger with embryonal tumors is similar to that outlined for children aged 3 years and younger with medulloblastoma. Aggressive surgical resection is reasonable, given the improved rate of survival for medulloblastomas and other ETMRs after total or near-total resection.[11] For more information, see the Treatment of younger children with medulloblastoma section.

Sources: 11 · Treatment of younger children with medulloblastoma

With the use of chemotherapy alone, outcome has been variable, with survival rates at 5 years ranging between 0% and 50%.[24-26]; [27][Level of evidence B4] The addition of craniospinal irradiation to chemotherapy-based regimens may successfully treat some children but with anticipated neurodevelopmental decline.[28][Level of evidence B4] Localized radiation therapy to the tumor site, either before or after chemotherapy, has been given, although data supporting its efficacy are unclear.

Sources: 24 · 26 · 27 · Level of evidence B4 · 28 · Level of evidence B4

Health professional · Childhood Nonmedulloblastoma Embryonal Tumors / Treatment of Childhood Nonmedulloblastoma Embryonal Tumors

Treatment of children older than 3 years

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Standard treatment options for children older than 3 years with newly diagnosed nonmedulloblastoma embryonal tumors, excluding AT/RTs, ETMRs, and FOXR2-activated tumors, include the following:

Surgery.

Sources: Surgery

Adjuvant radiation therapy.

Sources: Adjuvant radiation therapy.

Adjuvant chemotherapy.

Sources: Adjuvant chemotherapy

Health professional · Childhood Nonmedulloblastoma Embryonal Tumors / Treatment of Childhood Nonmedulloblastoma Embryonal Tumors / Treatment of children older than 3 years

Surgery

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Evidence (surgery):

Nonmedulloblastoma embryonal tumors are often amenable to resection. In reported case series, 50% to 75% of tumors in patients were totally or near-totally resected.[29,30]; [3][Level of evidence A1]

Sources: 29 · 30 · 3 · Level of evidence A1

Attempting aggressive surgical resection is the first step in the management of newly diagnosed nonmedulloblastoma embryonal tumors. Although previous studies did not demonstrate that the extent of resection is predictive of outcome,[29-31] one study demonstrated improved survival when the tumor was completely resected.[32][Level of evidence B4] A published study (COG-ACNS0332 [NCT00392327]) of molecularly classified nonmedulloblastoma embryonal tumors revealed improved overall survival (OS) for patients who had less than 1.5 cm2 of residual disease, compared with patients who had more than 1.5 cm2 of residual disease.[3][Level of evidence A1]

Sources: 29 · 31 · 32 · Level of evidence B4 · COG-ACNS0332 [NCT00392327] · 3 · Level of evidence A1

Health professional · Childhood Nonmedulloblastoma Embryonal Tumors / Treatment of Childhood Nonmedulloblastoma Embryonal Tumors / Treatment of children older than 3 years

Adjuvant radiation therapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

After surgery, children with nonmedulloblastoma embryonal tumors usually receive treatment similar to that received by children with high-risk medulloblastoma.

Conventionally, patients are treated with radiation to the entire neuraxis with local boost radiation therapy, as given for medulloblastoma.[31] Local boost radiation therapy may be problematic because of the size of the tumor and its location in the cerebral cortex. Also, there is no definitive evidence that craniospinal radiation therapy is superior to radiation to the primary tumor site alone in children with nondisseminated lesions.[29-31]

Sources: 31 · 29 · 31

Health professional · Childhood Nonmedulloblastoma Embryonal Tumors / Treatment of Childhood Nonmedulloblastoma Embryonal Tumors / Treatment of children older than 3 years

Adjuvant chemotherapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

The chemotherapeutic approaches during and after radiation therapy are similar to those used for children with high-risk medulloblastoma. The 3-year to 5-year OS rates range from 25% to 50%.[29-31]; [32,33][Level of evidence B4]; [34][Level of evidence C1]

Sources: 29 · 31 · 32 · 33 · Level of evidence B4 · 34 · Level of evidence C1

In a published study of nonpineal tumors that were diagnosed as CNS primitive neuroectodermal tumors (PNETs) by traditional pathology, 71% of cases were revealed to be glioblastoma or another diagnosis by DNA methylation studies. Patients with nonmedulloblastoma embryonal tumors (n = 36) (including pineoblastomas, n = 26) had a 5-year OS rate of 78.5% (95% confidence interval [CI], 62.2%–94.8%). In contrast, the patients with glioblastoma had a 5-year OS rate of 12% (95% CI, 0%–24.7%). The study showed no benefit for children who received carboplatin or isotretinoin.[3][Level of evidence A1] This study highlights the importance of molecular classification of tumors traditionally termed CNS-PNET.[4]

Sources: 3 · Level of evidence A1 · 4

Health professional · Childhood Nonmedulloblastoma Embryonal Tumors

Treatment of Childhood Embryonal Tumors With Multilayered Rosettes or Medulloepithelioma

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

A registry-based review of 159 patients with a confirmed molecular diagnosis of ETMR reported survival results for different treatments.[11]

Sources: 11

The 2-year event-free survival (EFS) and OS rates were 0% for patients treated with conventional chemotherapy without radiation therapy, regardless of the degree of surgical resection.

The 2-year EFS rate was 21% and the OS rate was 30% for patients who had a gross-total resection and were treated with high-dose chemotherapy without radiation therapy.

The 2-year EFS rate was 44% for children treated with high-dose chemotherapy and radiation therapy after a subtotal resection and 66% for patients treated with high-dose chemotherapy and radiation therapy after a gross-total resection.

The relative roles of focal radiation therapy versus craniospinal radiation therapy could not be assessed in this review.

In a separate, but possibly overlapping, international retrospective review, 49 patients with histologically confirmed (by the treating institution) ETMRs were treated between 1988 to 2017 in a variety of ways.[35] The 5-year progression-free survival rate was 18% (± 6%), and the OS rate was 24% (± 6%). Most survivors received radiation therapy, including both local and craniospinal treatment, and there was no clear difference in outcomes between the types and extent of radiation therapy. The relative benefits of conventional chemotherapy compared with high-dose chemotherapy could not be assessed.[5]

Sources: 35 · 5

In a subsequent publication, likely including some of the patients from the retrospective study, treatment was limited to only those who received chemotherapy and radiation therapy on the prospective P-HIT study or per the study protocol. The P-HIT study included postsurgery chemotherapy, high-dose chemotherapy, and radiation for some patients. In 35 patients with ETMRs, 8 long-term survivors were identified, 6 of whom had received either craniospinal or local radiation therapy, in addition to induction and high-dose chemotherapy. None of the patients who presented with brain stem disease survived. The 5-year survival was best for patients with localized disease, possibly for those treated with both induction and high-dose chemotherapy. The role of radiation therapy or the optimal volume of radiation therapy (local versus craniospinal) could not be determined.[10]

Sources: 10

These studies suggest that the outcome for children with ETMRs may not be as dire as suggested by initial studies, which found a 5-year survival rate of 25% or lower. Outcome is more favorable in children with localized disease at the time of diagnosis and those who were treated with aggressive postsurgical chemotherapy, including induction and high-dose consolidation treatment. The role of radiation therapy is still unproven, and there is no evidence that craniospinal radiation in patients with localized disease is superior to focal radiation therapy.[5,10,11]

Sources: 5 · 10 · 11

Health professional · Childhood Nonmedulloblastoma Embryonal Tumors

Treatment of CNS Neuroblastoma, FOXR2-Activated

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

The optimal treatment of patients with CNS neuroblastoma, FOXR2-activated tumors has not been confirmed by prospective studies. In a retrospective review of patients diagnosed between 1988 and 2007, the highest rates of survival were seen after complete or near-complete resections in patients with nonmetastatic tumors who also received craniospinal radiation therapy and possibly chemotherapy. With this type of approach, up to 75% of children (35 of 42) were alive 5 years after diagnosis and treatment. This tumor tends to occur in a somewhat older population than some of the other nonmedulloblastoma embryonal tumors.[5]

Sources: 5

Health professional · Childhood Pineoblastoma

Treatment Option Overview for Childhood Pineoblastoma

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Table 4 describes the treatment options for newly diagnosed and recurrent childhood pineoblastoma.

Sources: Table 4

Table 4. Treatment Options for Childhood Pineoblastoma
Treatment GroupTreatment Options
Newly diagnosed childhood pineoblastomaChildren aged 3 years and youngerBiopsy (for diagnosis) and total resection, if possible
Adjuvant chemotherapy
High-dose, marrow-ablative chemotherapy with autologous bone marrow rescue or peripheral stem cell rescue
Children older than 3 yearsSurgery
Adjuvant radiation therapy
Adjuvant chemotherapy
Recurrent childhood pineoblastomaThere are no standard treatment options. For more information, see the Treatment of Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors section.

Sources: Biopsy · Adjuvant chemotherapy · High-dose, marrow-ablative chemotherapy with autologous bone marrow rescue or peripheral stem cell rescue · Surgery · Adjuvant radiation therapy · Adjuvant chemotherapy · Treatment of Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors

Health professional · Childhood Pineoblastoma

Treatment of Childhood Pineoblastoma

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Health professional · Childhood Pineoblastoma / Treatment of Childhood Pineoblastoma

Treatment of children aged 3 years and younger

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

No standard treatment options currently exist for children aged 3 years and younger with pineoblastoma.[15] The following treatment approaches are available:

Sources: 15

Biopsy (for diagnosis) and total resection, if possible.

Sources: Biopsy (for diagnosis) and total resection, if possible

Adjuvant chemotherapy.

Sources: Adjuvant chemotherapy

High-dose, marrow-ablative chemotherapy with autologous bone marrow rescue or peripheral stem cell rescue.

Sources: High-dose, marrow-ablative chemotherapy with autologous bone marrow rescue or peripheral stem cell rescue

Health professional · Childhood Pineoblastoma / Treatment of Childhood Pineoblastoma / Treatment of children aged 3 years and younger

Biopsy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Biopsy and, if possible, total resection, is usually performed to diagnose pineoblastoma.

Health professional · Childhood Pineoblastoma / Treatment of Childhood Pineoblastoma / Treatment of children aged 3 years and younger

Adjuvant chemotherapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Children aged 3 years and younger with pineoblastoma are usually treated initially with chemotherapy in the hope of delaying, if not obviating, the need for radiation therapy.[16] Overall prognosis for this group remains very poor.[17-19] In two sequential, multicenter, prospective clinical trials, all five children younger than 3 years who were treated with chemotherapy died.[20][Level of evidence B4] In children responding to chemotherapy, the timing and amount of radiation therapy required after chemotherapy is unclear. The addition of craniospinal irradiation to chemotherapy-based regimens may successfully treat some children but with anticipated neurodevelopmental decline.[21][Level of evidence B4] Two large pooled analyses both revealed dismal survival for children younger than 3 or 4 years with pineoblastoma.[18,19]

Sources: 16 · 17 · 19 · 20 · Level of evidence B4 · 21 · Level of evidence B4 · 18 · 19

Health professional · Childhood Pineoblastoma / Treatment of Childhood Pineoblastoma / Treatment of children aged 3 years and younger

High-dose, marrow-ablative chemotherapy with autologous bone marrow rescue or peripheral stem cell rescue

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

High-dose, marrow-ablative chemotherapy with autologous bone marrow rescue or peripheral stem cell rescue has been used with some success in young children.[22][Level of evidence B4] Two pooled analyses also revealed this modality may have some efficacy.[18,19]

Sources: 22 · Level of evidence B4 · 18 · 19

Health professional · Childhood Pineoblastoma / Treatment of Childhood Pineoblastoma

Treatment of children older than 3 years

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Standard treatment options for children older than 3 years with newly diagnosed pineoblastoma include the following:

Surgery.

Sources: Surgery

Adjuvant radiation therapy.

Sources: Adjuvant radiation therapy.

Adjuvant chemotherapy.

Sources: Adjuvant chemotherapy

Health professional · Childhood Pineoblastoma / Treatment of Childhood Pineoblastoma / Treatment of children older than 3 years

Surgery

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Surgery is usually the initial treatment for patients with pineoblastoma to diagnose the tumor.[23] Total resections have been associated with better outcomes.

Sources: 23

Health professional · Childhood Pineoblastoma / Treatment of Childhood Pineoblastoma / Treatment of children older than 3 years

Adjuvant radiation therapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

The usual postsurgical treatment for patients with pineoblastoma begins with radiation therapy, although some trials have used preradiation chemotherapy. The total dose of radiation therapy to the tumor site is 54 Gy to 55.8 Gy using conventional fractionation.[13,14]

Sources: 13 · 14

Craniospinal irradiation with doses of 23.4 Gy to 36 Gy are also recommended because of the propensity of this tumor to disseminate throughout the subarachnoid space.[13,14,17]

Sources: 13 · 14 · 17

Health professional · Childhood Pineoblastoma / Treatment of Childhood Pineoblastoma / Treatment of children older than 3 years

Adjuvant chemotherapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Chemotherapy is usually given in the same way as outlined for high-risk medulloblastomas in children with nondisseminated disease at the time of diagnosis.[15] For more information, see the Treatment of children older than 3 years with high-risk medulloblastoma section.

Sources: 15 · Treatment of children older than 3 years with high-risk medulloblastoma

The 5-year disease-free survival rate exceeds 50% in children with localized disease at diagnosis who undergo aggressive resection.[13,14,24,25][Level of evidence A1] The Children's Oncology Group (COG) COG-ACNS0332 (NCT00392327) study of 36 patients with nonmedulloblastoma embryonal tumors (which included 26 pineoblastomas) reported a 5-year overall survival (OS) rate of 78.5% (95% confidence interval, 62.2%–94.8%).[25][Level of evidence A1]

Sources: 13 · 14 · 24 · 25 · Level of evidence A1 · COG-ACNS0332 (NCT00392327) · 25 · Level of evidence A1

For patients with disseminated disease at the time of diagnosis, survival is considerably poorer.[13,14] In the COG-ACNS0332 (NCT00392327) study, there was no significant difference in event-free survival or OS according to metastatic status.

Sources: 13 · 14 · COG-ACNS0332 (NCT00392327)

Health professional · Childhood Pineoblastoma / Treatment of Childhood Pineoblastoma

Treatment options under clinical evaluation for childhood pineoblastoma

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

For patients with pineoblastoma, a variety of different treatment approaches are under evaluation, including the use of higher doses of chemotherapy after radiation therapy supported by peripheral stem cell rescue and the use of chemotherapy during radiation therapy.

Early-phase therapeutic trials may be available for selected patients. These trials may be available via the COG, the Pediatric Brain Tumor Consortium, or other entities. Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: COG · Pediatric Brain Tumor Consortium · NCI website · ClinicalTrials.gov website

Health professional

Treatment of Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Recurrence of all forms of central nervous system (CNS) embryonal tumors is not uncommon and usually occurs within 36 months of treatment. However, recurrent tumors may also develop many years after initial treatment.[1-3] In such late relapses, especially those occurring 5 or more years after diagnosis, differentiation from secondary tumors such as high-grade gliomas can be difficult. Histological confirmation is recommended and usually required. In a 2021 report, a paired molecular cohort was assembled, consisting of 127 patients with tissue specimens available from both their primary medulloblastomas and subsequent tumors associated with relapse. Comparative molecular analyses were performed using the patient-matched tumor specimens. DNA methylation-based classification identified nine relapse cases (7%) as histologies other than medulloblastoma.[4] Disease may recur at the primary site or may be disseminated at the time of relapse. Sites of noncontiguous relapse may include the spinal leptomeninges, intracranial sites, and cerebrospinal fluid, in isolation or in any combination, and may be associated with primary tumor relapse.[1,2,5] Extraneural disease relapse is rare and is seen primarily in patients who were treated with radiation therapy alone.[6][Level of evidence C1]

Sources: 1 · 3 · 4 · 1 · 2 · 5 · 6 · Level of evidence C1

Studies have found that even in patients with nondisseminated disease at diagnosis, and independent of the dose of radiation therapy or the type of chemotherapy, approximately one-third of patients will experience a relapse at the primary tumor site alone, one-third at the primary tumor site plus distant sites, and one-third at distant sites without relapse at the primary site.[1,2,5]

Sources: 1 · 2 · 5

Health professional · Treatment of Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors

Treatment Options

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

There are no standard treatment options for recurrent childhood CNS embryonal tumors. For more information, see the Treatment for Recurrent Childhood CNS Atypical Teratoid/Rhabdoid Tumor section in Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment.

Sources: Treatment for Recurrent Childhood CNS Atypical Teratoid/Rhabdoid Tumor

For most children, treatment is palliative, and disease control is transient in patients previously treated with radiation therapy and chemotherapy, with more than 80% of patients progressing within 2 years.[3]; [7][Level of evidence C1] The temporal and spatial patterns of relapse differ between molecular subgroups. Patients with group 4 medulloblastomas present with delayed relapse compared with patients in other subgroups. In children who develop relapsed disease after radiation-sparing strategies, patients with group 4 and SHH medulloblastomas have higher rates of local relapse (42% and 39%, respectively), compared with patients with group 3 disease (17%).[8] For young children, predominantly those younger than 3 years at diagnosis who were never treated with radiation therapy, longer-term control with reoperation, radiation therapy, and chemotherapy is possible.[5,8-12]

Sources: 3 · 7 · Level of evidence C1 · 8 · 5 · 8 · 12

Treatment approaches may include the following:

Surgery.

Sources: Surgery

Radiation therapy.

Sources: Radiation therapy

Chemotherapy.

Sources: Chemotherapy

High-dose chemotherapy with stem cell rescue.

Sources: High-dose chemotherapy with stem cell rescue

Molecularly targeted therapy.

Sources: Molecularly targeted therapy

Health professional · Treatment of Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors / Treatment Options

Surgery

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

At the time of relapse, a complete evaluation for extent of recurrence is indicated for all embryonal tumors. Biopsy or surgical resection may be necessary for confirmation of relapse because other entities, such as secondary tumors and treatment-related brain necrosis, may be clinically indistinguishable from tumor recurrence. The need for surgical intervention must be individualized based on the initial tumor type, the length of time between initial treatment and the reappearance of the lesion, and clinical symptoms.

Health professional · Treatment of Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors / Treatment Options

Radiation therapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Patients with recurrent embryonal tumors who have already received radiation therapy and chemotherapy may be candidates for further radiation therapy depending on the site and dose of previous radiation. Treatment may include reirradiation at the primary tumor site, focal areas of radiation therapy to sites of disseminated disease, and craniospinal irradiation (CSI).[13,14] However, long-term survival has been observed in a subset of patients who received chemotherapy alone at the time of diagnosis and had local relapse. This finding was primarily noted in young children with SHH-activated disease.[8,15] In most cases, such therapy is palliative. Stereotactic radiation therapy and/or salvage chemotherapy can also be used.[16] For more information, see the Chemotherapy section.

Sources: 13 · 14 · 8 · 15 · 16 · Chemotherapy

One retrospective study reported the outcomes of infants and young children with relapsed medulloblastoma who were initially treated in a variety of different chemotherapy clinical trials without CSI.[8]

Sources: 8

One retrospective study reported the outcomes of infants and young children with relapsed medulloblastoma who were initially treated in a variety of different chemotherapy clinical trials without CSI.[8]

At the time of relapse, 73% of these children were treated with CSI-based regimens.

The 3-year postrelapse survival rate was 52.4% for patients treated with curative intent.

The 3-year postrelapse survival rates for children with SHH, group 3, and group 4 medulloblastoma who received salvage radiation therapy were 61%, 40%, and 79%, respectively. Patients with SHH disease were less likely to receive salvage radiation therapy.

Older age at diagnosis, local relapse, and the SHH infant subtype were associated with better postrelapse survival.

Health professional · Treatment of Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors / Treatment Options

Chemotherapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Recurrent CNS embryonal tumors can respond to chemotherapeutic agents used singularly or in combination, including cyclophosphamide, cisplatin, carboplatin, lomustine, etoposide, topotecan, temozolomide, the combination of irinotecan and temozolomide with or without bevacizumab, and antiangiogenic metronomic therapy.[9,17-27]; [28-30][Level of evidence B4] Approximately 30% to 50% of these patients have objective responses to conventional chemotherapy, but long-term disease control is rare.

Sources: 9 · 17 · 27 · 28 · 30 · Level of evidence B4

For select patients with recurrent medulloblastoma—primarily infants and young children who were treated at the time of diagnosis with chemotherapy alone and who developed local recurrence—long-term disease control may be obtained after further treatment with chemotherapy plus local radiation therapy. This potential may be greatest in patients who are able to undergo complete resection of the recurrent disease.[31][Level of evidence B4]; [32][Level of evidence C1]

Sources: 31 · Level of evidence B4 · 32 · Level of evidence C1

In a St. Jude Children’s Research Hospital study (SJYC07 [NCT00602667]), 29 patients with progressive disease received CSI (median dose, 36 Gy; interquartile range, 36–36). Of these 29 patients, 18 (62%) were alive at the time of publication, compared with 6 of 25 patients (24%) who did not receive CSI.[12][Level of evidence B4]

Sources: SJYC07 [NCT00602667]) · 12 · Level of evidence B4

Health professional · Treatment of Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors / Treatment Options

High-dose chemotherapy with stem cell rescue

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

For patients who have previously received radiation therapy, higher-dose chemotherapeutic regimens, supported with autologous bone marrow rescue or peripheral stem cell support, have been used with variable results.[10,11,33-36][Level of evidence B4]; [37-39][Level of evidence C1]

Sources: 10 · 11 · 33 · 36 · Level of evidence B4 · 37 · 39 · Level of evidence C1

With such regimens, objective response is frequent, occurring in 50% to 75% of patients. However, long-term disease control is obtained in fewer than 30% of patients and is seen primarily in patients in first relapse and those with only localized disease at the time of relapse.[11]; [36][Level of evidence B4]; [37][Level of evidence C1]

Sources: 11 · 36 · Level of evidence B4 · 37 · Level of evidence C1

Additionally, results from national trials for relapsed medulloblastoma that specified intent to transplant as part of their treatment plan showed that only approximately 5% of patients initiating retrieval therapy achieved long-term disease-free survival with this strategy.[36,40] Thus, studies that report from the time of transplant overestimate the benefit of transplant-based approaches for the total population of patients who have a relapse.

Sources: 36 · 40

Long-term disease control for patients with disseminated disease is infrequent.[41][Level of evidence C1]

Sources: 41 · Level of evidence C1

Health professional · Treatment of Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors / Treatment Options

Molecularly targeted therapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

With increased knowledge of the molecular and genetic changes associated with different subtypes of medulloblastoma, molecularly targeted therapy, also called precision therapy, is being actively explored in children with recurrent disease.

In patients with recurrent SHH-activated medulloblastomas, the SHH PTCH1 inhibitor vismodegib demonstrated radiographic responses in 3 of 12 pediatric patients. Two of the responses were sustained for less than 2 months, and one response was sustained for more than 6 months. Response was only seen in patients with upstream variants of the SHH pathway, at the level of PTCH1 or SMO.[42] However, because of the development of irreversible growth plate fusions, the use of vismodegib is limited to skeletally mature children.[43]

Sources: 42 · 43

Health professional · Treatment of Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors

Treatment Options Under Clinical Evaluation for Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 11, 2025. Captured 2026-09-09.

Early-phase therapeutic trials may be available for selected patients. These trials may be available via the Children's Oncology Group (COG), the Pediatric Brain Tumor Consortium, or other entities. Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: Children's Oncology Group (COG) · Pediatric Brain Tumor Consortium · NCI website · ClinicalTrials.gov website

For patients · General Information About Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

If your child has been diagnosed with medulloblastoma, other CNS embryonal tumor, or pineoblastoma, you likely have questions about how serious the cancer is and your child's chances of survival. The likely outcome or course of a disease is called prognosis.

The prognosis and treatment options depend on:

the type of tumor and where it is in the brain

whether the cancer has spread within the brain and spinal cord when the tumor is found

the age of the child when the tumor is found

how much of the tumor remains after surgery

whether there are certain changes in the chromosomes, genes, or brain cells

Sources: chromosomes

whether the tumor has just been diagnosed or has recurred (come back)

Sources: recurred

No two people are alike, and responses to treatment can vary greatly. Your child's cancer care team is in the best position to talk with you about your child's prognosis.

For patients · Staging Childhood Medulloblastoma, Other Central Nervous System Embryonal Tumors, and Pineoblastoma

Medulloblastoma, other CNS embryonal tumors, and pineoblastoma in children are treated based on the tumor type and the child's age.

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

Cancer stage describes the extent of cancer in the body, such as the size of the tumor, whether it has spread, and how far it has spread from where it first formed. There is no staging system used for childhood medulloblastoma, other central nervous system (CNS) embryonal tumors, or pineoblastoma, but the tests and procedures done to diagnose the cancer are also used to help plan treatment.

Sources: staging system · medulloblastoma · central nervous system · embryonal tumors, · pineoblastoma, · diagnose

Treatment of other CNS embryonal tumors and pineoblastoma in children is based on the child's age. Children aged 3 years and younger may be given different treatment than children older than 3 years.

For patients · Staging Childhood Medulloblastoma, Other Central Nervous System Embryonal Tumors, and Pineoblastoma

Treatment of medulloblastoma in children older than 3 years also depends on whether the tumor is average risk or high risk.

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

For patients · Staging Childhood Medulloblastoma, Other Central Nervous System Embryonal Tumors, and Pineoblastoma / Treatment of medulloblastoma in children older than 3 years also depends on whether the tumor is average risk or high risk.

Average risk

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

Medulloblastomas are called average risk when all of the following are true:

The tumor was completely removed by surgery or there was only a very small amount remaining.

Sources: surgery

The cancer has not spread to other parts of the body.

For patients · Staging Childhood Medulloblastoma, Other Central Nervous System Embryonal Tumors, and Pineoblastoma / Treatment of medulloblastoma in children older than 3 years also depends on whether the tumor is average risk or high risk.

High risk

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

Medulloblastomas are called high risk if any of the following are true:

Some of the tumor was not removed by surgery.

The cancer has spread to other parts of the brain or spinal cord or to other parts of the body.

In general, cancer is more likely to recur (come back) after treatment in patients with a high-risk tumor.

Sources: recur

For patients · Staging Childhood Medulloblastoma, Other Central Nervous System Embryonal Tumors, and Pineoblastoma

The results of the tests and procedures done to diagnose medulloblastoma, other CNS embryonal tumors, and pineoblastoma in children are used to plan cancer treatment.

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

If your child is diagnosed with medulloblastoma, another type of CNS embryonal tumor, or pineoblastoma, they will be referred to a pediatric oncologist/neuro-oncologist. This is a doctor who specializes in staging and treating childhood cancers. They will recommend tests to determine the extent (stage) of cancer. Some of the tests used to diagnose the cancer are repeated after surgery. This is to find out how much tumor remains after surgery and to see if the cancer has spread from the brain to the spine or other parts of the body. It is important to know if the cancer has spread in order to plan the best treatment. Learn more about diagnostic tests in the General Information section.

Sources: pediatric oncologist · neuro-oncologist · spine · General Information

The following tests may be used to find out if the cancer has spread beyond the brain and spinal cord:

Bone marrow aspiration and biopsy are procedures in which a sample of bone marrow and bone is removed from the hipbone or breastbone using a special needle. A pathologist views the sample under a microscope to look for signs of cancer. A bone marrow aspiration and biopsy are only done when there are signs the cancer has spread to the bone marrow.

Sources: Bone marrow aspiration · biopsy · bone marrow · breastbone · pathologist · signs

Bone scan is a procedure to check if there are rapidly dividing cells, such as cancer cells, in the bone. A very small amount of radioactive material is injected into a vein and travels through the bloodstream. The radioactive material collects in the bones with cancer and is detected by a scanner. A bone scan is only done when there are signs or symptoms that the cancer has spread to the bone.

Sources: Bone scan · radioactive · injected · scanner · symptoms

For patients · Staging Childhood Medulloblastoma, Other Central Nervous System Embryonal Tumors, and Pineoblastoma

Sometimes childhood medulloblastoma and other central nervous system embryonal tumors come back after treatment.

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

Childhood medulloblastoma and other types of CNS embryonal tumors most often recur (come back) within 3 years after treatment but may come back many years later. Recurrent childhood medulloblastoma and other CNS embryonal tumors may come back in the same place as the original tumor and/or in a different place in the brain or spinal cord.

For patients

Treatment Option Overview

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

There are different types of treatment for children who have medulloblastoma and other central nervous system (CNS) embryonal tumors.

Children who have medulloblastoma, other CNS embryonal tumors, and pineoblastoma should have their treatment planned by a team of health care providers who are experts in treating brain tumors in children.

The following types of treatment may be used:

The following types of treatment may be used:

Surgery

Radiation therapy

Chemotherapy

High-dose chemotherapy with autologous stem cell rescue

Targeted therapy

New types of treatment are being tested in clinical trials.

For patients · Treatment Option Overview

There are different types of treatment for children who have medulloblastoma and other central nervous system (CNS) embryonal tumors.

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

There are different types of treatment for children and adolescents with medulloblastoma, other types of CNS embryonal tumors, or pineoblastoma. You and your child's cancer care team will work together to decide treatment. Many factors will be considered, such as your child's overall health and whether the tumor is newly diagnosed or has come back.

Sources: adolescents · medulloblastoma · CNS · embryonal tumors · pineoblastoma

For patients · Treatment Option Overview

Children who have medulloblastoma, other CNS embryonal tumors, and pineoblastoma should have their treatment planned by a team of health care providers who are experts in treating brain tumors in children.

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

A pediatric oncologist, a doctor who specializes in treating children with cancer, oversees treatment of medulloblastoma, other CNS embryonal tumors, and pineoblastoma. The pediatric oncologist works with other pediatric health care providers who are experts in treating children with brain tumors and who specialize in certain areas of medicine. Other specialists may include:

pediatrician

Sources: pediatrician

neurosurgeon

Sources: neurosurgeon

neurologist

Sources: neurologist

neuropathologist

Sources: neuropathologist

neuroradiologist

Sources: neuroradiologist

rehabilitation specialist

Sources: rehabilitation specialist

radiation oncologist

Sources: radiation oncologist

psychologist

Sources: psychologist

Your child's treatment plan will include information about the cancer, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's cancer care team before treatment begins about what to expect. For help every step of the way, see our downloadable booklet, Children with Cancer: A Guide for Parents.

Sources: side effects · Children with Cancer: A Guide for Parents

For patients · Treatment Option Overview

The following types of treatment may be used:

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment may be used:

Surgery

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

Surgery is used to diagnose and treat childhood medulloblastoma, other CNS embryonal tumors, and pineoblastoma as described in the General Information section of this summary.

Sources: General Information

After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy, radiation therapy, or both to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.

Sources: chemotherapy · radiation therapy

For patients · Treatment Option Overview / The following types of treatment may be used:

Radiation therapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Medulloblastoma, other CNS embryonal tumors, or pineoblastoma in children may be treated with external beam radiation therapy. External beam radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.

Sources: x-rays · radiation · external beam radiation therapy

Certain ways of giving external radiation therapy can help keep radiation from damaging nearby healthy tissue. These types of radiation therapy include:

Conformal radiation therapy uses a computer to make a 3-dimensional (3-D) picture of the tumor and shapes the radiation beams to fit the tumor. This allows a high dose of radiation to reach the tumor and causes less damage to nearby healthy tissue.

Sources: Conformal radiation therapy · 3-dimensional · dose

Stereotactic radiation therapy uses a machine that aims radiation directly at the tumor, causing less damage to nearby healthy tissue. The total dose of radiation is divided into several smaller doses given over several days. A rigid head frame is attached to the skull to keep the head still during this radiation treatment. This procedure is also called stereotactic radiosurgery and stereotaxic radiation therapy.

Sources: Stereotactic radiation therapy · skull

Because radiation therapy can affect growth and brain development in young children, especially children who are 3 years or younger, chemotherapy may be given to delay or reduce the need for radiation therapy.

Radiation therapy to the brain can also affect growth and development in children older than 3 years. For this reason, clinical trials are studying new ways of giving radiation that may have fewer side effects than standard methods.

Sources: growth and development · clinical trials · standard

For patients · Treatment Option Overview / The following types of treatment may be used:

Chemotherapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemotherapy may be given alone or with other types of treatment, such as radiation therapy.

To treat medulloblastoma, other CNS embryonal tumors, and pineoblastoma, chemotherapy is taken by mouth or injected into a vein. When given this way, the drugs enter the bloodstream and can reach cancer cells throughout the body. Chemotherapy that may be used alone or in combination includes:

Sources: injected

carboplatin

Sources: carboplatin

cisplatin

Sources: cisplatin

cyclophosphamide

Sources: cyclophosphamide

etoposide

Sources: etoposide

irinotecan

Sources: irinotecan

lomustine

Sources: lomustine

methotrexate

Sources: methotrexate

temozolomide

Sources: temozolomide

thiotepa

Sources: thiotepa

topotecan

Sources: topotecan

vincristine

Sources: vincristine

Other chemotherapy drugs not listed here may also be used.

Learn more about Chemotherapy to Treat Cancer.

Sources: Chemotherapy to Treat Cancer

For patients · Treatment Option Overview / The following types of treatment may be used:

High-dose chemotherapy with autologous stem cell rescue

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

High doses of chemotherapy are given to kill cancer cells. This cancer treatment destroys healthy cells, including blood-forming cells. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.

Sources: Stem cell transplant · Stem cells · bone marrow · infusion

For patients · Treatment Option Overview / The following types of treatment may be used:

Targeted therapy

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

Targeted therapy uses drugs or other substances to block the action of specific enzymes, proteins, or other molecules involved in the growth and spread of cancer cells.

Sources: enzymes · proteins · molecules

Vismodegib may be used to treat recurrent medulloblastoma in children who have finished growing.

Sources: Vismodegib · recurrent

Targeted therapy is also being studied for the treatment of childhood medulloblastoma and other CNS embryonal tumors that have recurred (come back) after treatment.

Learn more about Targeted Therapy to Treat Cancer.

Sources: Targeted Therapy to Treat Cancer

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. For some patients, taking part in a clinical trial may be the best treatment choice.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trial search · ClinicalTrials.gov

Learn more at Clinical Trials Information for Patients and Caregivers. Because cancer in children is rare, taking part in a clinical trial should be considered. Some clinical trials are open only to patients who have not started treatment.

Sources: Clinical Trials Information for Patients and Caregivers

For patients

Treatment of Childhood Medulloblastoma

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Younger children with medulloblastoma

Treatment of newly diagnosed medulloblastoma in children aged 3 years and younger includes:

Sources: medulloblastoma

Surgery to remove as much of the tumor as possible, followed by chemotherapy.

Other treatments that may be given after surgery include:

High-dose systemic and intraventricular chemotherapy.

Sources: systemic · intraventricular

High-dose chemotherapy with stem cell rescue.

Sources: High-dose chemotherapy · stem cell rescue

Chemotherapy with or without radiation therapy to the area where the tumor was removed.

Children older than 3 years with average-risk medulloblastoma

Treatment of newly diagnosed average-risk medulloblastoma in children older than 3 years includes:

Surgery to remove as much of the tumor as possible. This is followed by radiation therapy to the brain and spinal cord. Chemotherapy may also be given during and after radiation therapy.

Surgery to remove the tumor, radiation therapy, and high-dose chemotherapy with stem cell rescue.

Children older than 3 years with high-risk medulloblastoma

Treatment of newly diagnosed high-risk medulloblastoma in children older than 3 years includes:

Surgery to remove as much of the tumor as possible. This is followed by a larger dose of radiation therapy to the brain and spinal cord than the dose given for average-risk medulloblastoma. Chemotherapy is also given during and after radiation therapy.

Surgery to remove the tumor, radiation therapy, and high-dose chemotherapy with stem cell rescue.

For patients

Treatment of Other CNS Embryonal (nonmedulloblastoma) Tumors in Children

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Children aged 3 years and younger with nonmedulloblastoma, nonmedulloepithelioma embryonal tumors

Treatment of newly diagnosed nonmedulloblastoma, nonmedulloepithelioma embryonal tumors in children 3 years or younger includes:

Sources: embryonal tumors

Surgery to remove as much of the tumor as possible, followed by chemotherapy.

Children older than 3 years with nonmedulloblastoma, nonmedulloepithelioma embryonal tumors

Treatment of newly diagnosed nonmedulloblastoma, nonmedulloepithelioma embryonal tumors in children older than 3 years includes:

Surgery to remove as much of the tumor as possible. This is followed by radiation therapy to the brain and spinal cord. Chemotherapy is also given during and after radiation therapy.

Children with embryonal tumors with multilayered rosettes or medulloepithelioma

Treatment of newly diagnosed embryonal tumor with multilayered rosettes (ETMR) or medulloepithelioma may include:

Surgery to remove as much of the tumor as possible. This is followed by chemotherapy. Radiation therapy may also be given.

Surgery to remove the tumor, followed by high-dose chemotherapy with stem cell rescue.

Sources: high-dose chemotherapy · stem cell rescue

Children with CNS neuroblastoma

Treatment of newly diagnosed CNS neuroblastoma may include:

Sources: neuroblastoma

Surgery to remove as much of the tumor as possible. This is followed by radiation therapy to the brain and spinal cord. Chemotherapy may also be given.

For patients

Treatment of Childhood Pineoblastoma

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Children aged 3 years and younger

Treatment of newly diagnosed pineoblastoma in children aged 3 years and younger includes:

Sources: pineoblastoma

Biopsy to diagnose pineoblastoma and surgery to remove as much of the tumor as possible. Chemotherapy is usually given after surgery.

Sources: Biopsy

Surgery followed by high-dose chemotherapy with stem cell rescue.

Sources: high-dose chemotherapy · stem cell rescue

If the tumor responds to chemotherapy, radiation therapy is given when the child is older.

Sources: responds

Children older than 3 years

Treatment of newly diagnosed pineoblastoma in children older than 3 years includes:

Surgery to remove as much of the tumor as possible. This is followed by radiation therapy to the brain and spinal cord and chemotherapy.

For patients

Treatment of Recurrent Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment for recurrent childhood medulloblastoma and other CNS embryonal tumors may include:

Sources: recurrent · medulloblastoma · CNS · embryonal tumors

Biopsy to diagnose medulloblastoma and other CNS embryonal tumors. Surgery to remove as much of the tumor as possible may be done.

Sources: Biopsy

For children who previously received radiation therapy and chemotherapy, treatment may include repeat radiation at the site where the cancer started and where the tumor has spread. Stereotactic radiation therapy and/or chemotherapy may also be used.

Sources: Stereotactic radiation therapy

For infants and young children who previously received chemotherapy only and have a local recurrence, treatment may be chemotherapy with radiation therapy to the tumor and the area close to it. Surgery to remove the tumor may also be done.

Sources: local recurrence

For patients who previously received radiation therapy, high-dose chemotherapy and stem cell rescue may be used. It is not known whether this treatment improves survival.

Sources: high-dose chemotherapy · stem cell rescue

Targeted therapy with a signal transduction inhibitor (vismodegib) for patients whose cancer has certain changes in the genes.

Sources: signal transduction inhibitor · vismodegib · genes

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients · Side Effects

The tumor and the treatment may cause symptoms that continue after treatment ends.

Source: Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: December 2, 2024. Captured 2026-09-09.

Signs or symptoms caused by the tumor may begin before the cancer is diagnosed and continue for months or years. It is important to talk with your child's doctors about signs or symptoms caused by the tumor that may continue after treatment.

Sources: Signs · symptoms

Cancer treatments can cause side effects. Which side effects your child might have depends on the type of treatment they receive, the dose, and how their body reacts. Talk with your child's treatment team about which side effects to look for and ways to manage them.

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

Problems from cancer treatment that begin 6 months or later after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include:

Physical problems that affect:

Physical problems that affect:

bone and muscle growth and development

thyroid, heart, or hearing function

Sources: thyroid

Changes in mood, feelings, thinking, learning, or memory

Second cancers (new types of cancer), such as thyroid or other brain tumors

Sources: Second cancers · brain tumors

Children diagnosed with medulloblastoma may have certain problems after surgery or radiation therapy, such as changes in the ability to think, learn, and pay attention. Also, cerebellar mutism syndrome may occur after surgery. Signs of this syndrome include:

Sources: cerebellar mutism syndrome

delayed ability to speak

trouble swallowing and eating

loss of balance, trouble walking, and worsening handwriting

loss of muscle tone

mood swings and changes in personality

Some late effects may be treated or controlled. It is important to talk with your child's doctors about the effects cancer treatment can have on your child and the types of symptoms to expect after cancer treatment has ended. Learn more about Late Effects of Treatment for Childhood Cancer.

Sources: Late Effects of Treatment for Childhood Cancer

Studies

Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor

NCT00006461 · COMPLETED · phase3

Untreated Childhood Medulloblastoma, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor

ClinicalTrials.gov record

Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

NCT00085735 · COMPLETED · phase3

Medulloblastoma

ClinicalTrials.gov record

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

NCT00392327 · COMPLETED · phase3

Anaplastic Medulloblastoma, Medulloblastoma

ClinicalTrials.gov record

A Study of Pemetrexed in Children With Recurrent Cancer

NCT00520936 · COMPLETED · phase2

Osteosarcoma, Medulloblastoma, Sarcoma, Ewing's, Neuroblastoma (Measurable Disease), Neuroblastoma (Metaiodobenzylguanidine, Positive Evaluable), Rhabdomyosarcoma, Ependymoma,...

ClinicalTrials.gov record

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

NCT00602667 · ACTIVE NOT RECRUITING · phase2

Brain and Central Nervous System Tumors

ClinicalTrials.gov record

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

NCT01878617 · ACTIVE NOT RECRUITING · phase2

Medulloblastoma

ClinicalTrials.gov record

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma

NCT02017964 · COMPLETED · phase2

Desmoplastic/Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma With Extensive Nodularity, Nevoid Basal Cell Carcinoma Syndrome

ClinicalTrials.gov record

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

NCT02724579 · ACTIVE NOT RECRUITING · phase2

Medulloblastoma

ClinicalTrials.gov record

Disease and treatment settings

Childhood Central Nervous System Embryonal Tumors

Disease and treatment setting

Central Nervous System Embryonal Tumors in children and adolescents

Childhood Medulloblastoma

Disease and treatment setting

Medulloblastoma in children and adolescents

recurrent Childhood Central Nervous System Embryonal Tumors

Disease and treatment setting

Treatment of Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors

recurrent Childhood Medulloblastoma

Disease and treatment setting

Treatment of Recurrent Childhood Medulloblastoma and Other CNS Embryonal Tumors